无创门脉高压标志物可预测超重或肥胖代偿期进展性慢性肝病患者的失代偿
本研究纳入272例使用XL探头肝硬度≥10 kPa的超重或肥胖代偿期进展性慢性肝病患者,评估肝硬度、CAP、LSPS及门脉高压风险评分与失代偿及严重细菌感染的关联。中位随访17个月,12例发生失代偿,肝硬度、LSPS和门脉高压风险评分预测失代偿的AUROC分别为0.848、0.881和0.890。在非酒精性脂肪性肝炎患者中,肝硬度和CAP与失代偿及严重细菌感染独立相关。
要点
- 肝硬度、LSPS和门脉高压风险评分可识别超重或肥胖cACLD患者的失代偿风险。
- CAP≥220 dB/m与失代偿风险降低独立相关。
- 非酒精性脂肪性肝炎患者中肝硬度和CAP与失代偿及严重细菌感染独立相关。
核心结论
- 肝硬度、LSPS和门脉高压风险评分可识别超重或肥胖cACLD患者中失代偿和严重细菌感染风险增加者。
研究设计与样本
- 多中心队列研究,纳入272例使用XL探头肝硬度≥10 kPa的cACLD患者,中位随访17个月。
主要发现
- 12例发生失代偿,5例发生严重细菌感染。
- 肝硬度、LSPS和门脉高压风险评分预测失代偿的AUROC分别为0.848(95%CI 0.720-0.976;P<.0001)、0.881(95%CI 0.798-0.954;P<.0001)和0.890(95%CI 0.814-0.966;P<.0001)。
- 在非酒精性脂肪性肝炎患者中,肝硬度和CAP与失代偿及严重细菌感染独立相关。
- CAP≥220 dB/m与失代偿风险降低相关(HR 0.043,95%CI 0.004-0.476;P=.01)。
关键数值与推荐
- 肝硬度≥10 kPa(XL探头)定义cACLD。
- CAP≥220 dB/m与失代偿风险降低相关(HR 0.043,95%CI 0.004-0.476;P=.01)。
临床怎么用
- 对于超重或肥胖的cACLD患者,可采用肝硬度、LSPS和门脉高压风险评分进行失代偿风险评估。
- CAP检测可能有助于进一步风险分层。
局限性
- 失代偿事件数较少(12例),结果需更大样本验证。
- 随访时间较短(中位17个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Some patients with compensated advanced chronic liver disease (cACLD) require use of an extralarge probe for liver stiffness measurement (LSM), owing to overweight or obesity. However, the ability of noninvasive markers of portal hypertension and the controlled attenuation parameter (CAP) to determine which of these patients are at risk for decompensation has not been fully assessed. METHODS: We collected data from 272 patients with cACLD (LSM ≥10 kPa by XL probe; 57% with nonalcoholic steatohepatitis; mean body mass index, 33.8 ± 6.5 kg/m2; median Child-Pugh score, 5; median LSM, 16.8 kPa; mean CAP, 318 ± 66 dB/m) evaluated at 2 academic centers from 2015 through 2018. We collected clinical data on decompensation (ascites, portal hypertension bleeding, jaundice, hepatic encephalopathy) and severe bacterial infections; patients were followed up for a median of 17 months (interquartile range, 11-24 mo). We evaluated associations between these events and LSM, CAP, LSM∗spleen size/platelet count (LSPS), and portal hypertension risk scores. RESULTS: Decompensation occurred in 12 patients and severe bacterial infections developed in 5 patients. LSM, LSPS, and the portal hypertension risk score identified patients with decompensation with area under the receiver operating characteristic curve values of 0.848 (95% CI, 0.720-0.976; P < .0001), 0.881 (95% CI, 0.798-0.954; P < .0001), and 0.890 (95% CI, 0.814-0.966; P < .0001), respectively. In multivariate Cox regression analysis, in patients with nonalcoholic steatohepatitis, LSM and CAP were associated independently with decompensation and severe bacterial infection; CAP ≥ 220 dB/m was associated with a reduced risk of decompensation (hazard ratio, 0.043, 95% CI, 0.004-0.476; P = .01). CONCLUSIONS: LSM, LSPS, and the portal hypertension risk score identify obese or overweight patients with cACLD who are at increased risk of decompensation and severe bacterial infection.
引用
- Mendoza Y, Cocciolillo S, Murgia G, et al. Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32289534. doi:10.1016/j.cgh.2020.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。